Posted by Michael Wonder on 29 Mar 2023
Hansa Biopharma announces positive reimbursement decision in Spain for Idefirix (imlifidase) as desensitisation treatment for highly sensitised patients in kidney transplantation
29 March 2023 - Hansa Biopharma today announced that the Spanish Minister of Health (Ministerio de Sanidad) has granted access and reimbursement to Idefirix, the company’s first in class treatment, for the desensitisation of highly sensitised adult patients prior to kidney transplant from a deceased donor.
The positive reimbursement decision follows the conditional approval granted by EMA in August 2020.
